Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study. (Record no. 8357)

000 -LEADER
fixed length control field 04221nam a22006377a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 200131s20192019 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1522-1946
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1002/ccd.28661 [doi]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
Classification number 31883294
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Garcia-Garcia, Hector M
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Yacob, Omar
190 ## -
-- Adamo M
190 ## -
-- Ando G
190 ## -
-- Boccuzzi G
190 ## -
-- Briguori C
190 ## -
-- Calabro P
190 ## -
-- Contarini M
190 ## -
-- Diletti R
190 ## -
-- Frigoli E
190 ## -
-- Garcia-Garcia HM
190 ## -
-- Garducci S
190 ## -
-- Karagiannis A
190 ## -
-- Limbruno U
190 ## -
-- Palmieri C
190 ## -
-- Picchi A
190 ## -
-- Rigattieri S
190 ## -
-- Russo F
190 ## -
-- Sardella G
190 ## -
-- Soud M
190 ## -
-- Valgimigli M
190 ## -
-- Varbella F
190 ## -
-- Yacob O
190 ## -
-- Zimarino M
245 ## - TITLE STATEMENT
Title Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study.
251 ## -
-- Catheterization & Cardiovascular Interventions. 2019 Dec 28
252 ## -
-- Catheter Cardiovasc Interv. 2019 Dec 28
253 ## -
-- Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2019
260 ## - PUBLICATION, DISTRIBUTION, ETC.
-- aheadofprint
269 ## -
-- FY2020
501 ## - WITH NOTE
With note Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006
520 ## - SUMMARY, ETC.
Summary, etc. BACKGROUND: Residual stent strut thrombosis after primary percutaneous coronary intervention (PCI), negatively affects myocardial perfusion, may increase stent thrombosis risk, and it is associated with neointima hyperplasia at follow-up.
520 ## - SUMMARY, ETC.
Summary, etc. CONCLUSIONS: The administration of bivalirudin after primary PCI significantly reduces residual stent strut thrombosis when compared to UFH. This observation should be considered hypothesis-generating since the heparin-treated patients were not randomly allocated. Copyright (c) 2019 Wiley Periodicals, Inc.
520 ## - SUMMARY, ETC.
Summary, etc. METHODS: Multi-vessel STEMI patients undergoing primary PCI and requiring staged intervention were selected among those randomly allocated to two different bivalirudin infusion regimens in the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) Treatment-Duration study. Those receiving heparin only were enrolled into a registry arm. Optical coherence tomography (OCT) of the infarct-related artery was performed at the end of primary PCI and 3-5 days thereafter during a staged intervention. The primary endpoint was the change in minimum flow area (DELTAMinFA) defined as (stent area + incomplete stent apposition [ISA] area) - (intraluminal defect + tissue prolapsed area) between the index and staged PCI.
520 ## - SUMMARY, ETC.
Summary, etc. OBJECTIVES: To study the effectiveness of any bivalirudin infusion versus unfractionated heparin (UFH) infusion in reducing residual stent strut thrombosis in patients with ST-elevation myocardial infarction (STEMI).
520 ## - SUMMARY, ETC.
Summary, etc. RESULTS: 123 patients in bivalirudin arm and 28 patients in the UFH arm were included. Mean stent area, percentage of malapposed struts, and mean percent thrombotic area were comparable after index or staged PCI. The DELTAMinFA in the bivalirudin group was 0.25 versus 0.05 mm2 in the UFH group, which resulted in a between-group significant difference of 0.36 [95% CI: (0.05, 0.71); p = .02]. This was mostly related to a decrease in tissue protrusion in the bivalirudin group (p = .03). There was a trend towards more patients in the bivalirudin group who achieved a 5% difference in the percentage of OCT frames with the area >5% (p = .057).
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Geographic name MedStar Heart & Vascular Institute
657 ## - INDEX TERM--FUNCTION
Function Journal Article
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier https://dx.doi.org/10.1002/ccd.28661
857 ## -
-- https://dx.doi.org/10.1002/ccd.28661
858 ## -
-- Garcia-Garcia, Hector M
-- https://orcid.org/0000-0001-5100-0471
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Permanent Location Current Location Date acquired Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 2020-01-31 31883294 2020-01-31 2020-01-31 Journal Article

Powered by Koha